Gilead Sciences entered a licensing agreement with Genhouse Bio to acquire rights to a clinical‑ready MAT2A inhibitor designed to exploit synthetic lethality in MTAP‑deleted tumors. The deal is valued at roughly $1.5 billion in potential milestones and royalties, signaling Gilead’s strategic expansion into targeted oncology modalities. Gilead will support global development and commercialization, leveraging its oncology capabilities to advance the program through registration‑enabling studies. Synthetic lethality approaches targeting metabolic vulnerabilities remain a growing corner of oncology drug development, and this transaction adds a clinic‑stage small molecule to Gilead’s cancer pipeline.